Condition: Metastatic Breast Cancer · Sponsor: The Netherlands Cancer Institute
This is a single center, non-blinded, multi-cohort, non-comparative phase II trial to study the safety and efficacy of tiragolumab with atezolizumab and/or ipilimumab in advanced triple-negative breast cancer.
This description comes directly from the study's public registry record.
Marleen Kok, MD · +31205129111 · m.kok@nki.nl
Manon de Graaf, MD · +31205129111
Always discuss trial participation with your own doctor first.
| Antoni van Leeuwenhoek | Amsterdam, North Holland, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06342037